Paris (France), 01 July 2008
Ipsen completes purchase of Apokyn®, Vernalis US commercial operations and share subscription
Ipsen (Euronext: IPN) today announced that, following shareholder approval of Vernalis plc (LSE: VER), Ipsen has completed its purchase of Apokyn® and Vernalis’ US Commercial Operations.
Ipsen (Euronext: IPN) today announced that, following shareholder approval of Vernalis plc (LSE: VER), Ipsen has completed its purchase of Apokyn® and Vernalis’ US Commercial Operations.
Paris (France) and Basel (Switzerland), 10 June 2008
Roche moves investigational diabetes drug, Taspoglutide, into Phase III clinical trials
Positive Phase II results of Roche and Ipsen’s first once-weekly human GLP-1 presented at the American Diabetes Association congress.
Positive Phase II results of Roche and Ipsen’s first once-weekly human GLP-1 presented at the American Diabetes Association congress.
Paris (France), 09 June 2008
“Multiple sclerosis: From Pathogenesis to Therapy”
The fourth meeting in the “Emergence & Convergence” series jointly organised by Nature Medicine, Nature Immunology and La Fondation Ipsen.
The fourth meeting in the “Emergence & Convergence” series jointly organised by Nature Medicine, Nature Immunology and La Fondation Ipsen.
